Eli Lilly Announces Strong Second Quarter 2025 Results and Raises Full-Year Guidance

Details

The company raised its full-year revenue guidance to the range of $60 billion to $62 billion and EPS guidance to the range of $20.85 to $22.10 on a reported basis and $21.75 to $23.00 on a non-GAAP basis. The Q2 2025 EPS increased 92% to $6.29 on a reported basis and 61% to $6.31 on a non-GAAP basis. Additionally, the company provided updates on regulatory, clinical, and business development activities.

Items reported

Exhibits (1)

About Eli Lilly and Company

Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.